

Wouter W De Herder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7881406/publications.pdf>

Version: 2024-02-01

213
papers

14,536
citations

26630

56
h-index

20358

116
g-index

220
all docs

220
docs citations

220
times ranked

9974
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastroenteropancreatic neuroendocrine tumours. <i>Lancet Oncology</i> , The, 2008, 9, 61-72.	10.7	1,474
2	TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 395-401.	2.8	1,403
3	Octreotide. <i>New England Journal of Medicine</i> , 1996, 334, 246-254.	27.0	1,077
4	Radiolabeled Somatostatin Analog [¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 2754-2762.	1.6	602
5	NANETS Treatment Guidelines. <i>Pancreas</i> , 2010, 39, 735-752.	1.1	494
6	Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4617-4624.	7.0	399
7	ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016, 103, 119-124.	2.5	380
8	Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line <i>AIP</i> Mutations and Pituitary Adenomas: An International Collaborative Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E373-E383.	3.6	323
9	Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma. <i>Neuroendocrinology</i> , 2006, 84, 183-188.	2.5	248
10	ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016, 103, 139-143.	2.5	241
11	Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. <i>Endocrine-Related Cancer</i> , 2014, 21, R153-R163.	3.1	238
12	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. <i>Endocrine Pathology</i> , 2022, 33, 115-154.	9.0	227
13	Consensus on biomarkers for neuroendocrine tumour disease. <i>Lancet Oncology</i> , The, 2015, 16, e435-e446.	10.7	217
14	Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.. <i>Endocrine-Related Cancer</i> , 2003, 10, 451-458.	3.1	189
15	The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomas <i>in Vitro</i> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1577-1585.	3.6	178
16	Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. <i>Endocrine-Related Cancer</i> , 2012, 19, 657-666.	3.1	169
17	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. <i>Endocrine-Related Cancer</i> , 2015, 22, 745-757.	3.1	155
18	Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide. <i>Neuroendocrinology</i> , 2004, 80, 244-251.	2.5	152

#	ARTICLE	IF	CITATIONS
19	X-linked acro gigantism syndrome: clinical profile and therapeutic responses. <i>Endocrine-Related Cancer</i> , 2015, 22, 353-367.	3.1	151
20	Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4598-4601.	3.6	146
21	A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 638-645.	3.6	138
22	Subacute haematotoxicity after PRRT with ¹⁷⁷ Lu-DOTA-octreotate: prognostic factors, incidence and course. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 453-463.	6.4	125
23	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017, 105, 245-254.	2.5	122
24	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. <i>Neuroendocrinology</i> , 2017, 105, 266-280.	2.5	122
25	Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3288-3296.	3.6	116
26	Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. <i>Endocrine Reviews</i> , 2020, 41, 371-403.	20.1	116
27	Biochemistry of neuroendocrine tumours. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 33-41.	4.7	112
28	Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1118-1124.	3.6	109
29	Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³]octreotate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 749-755.	6.4	104
30	Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 439-451.	1.2	101
31	Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³]Octreotate. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1647-1653.	5.0	97
32	MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. <i>BMC Medicine</i> , 2016, 14, 182.	5.5	95
33	Symptomatic and Radiological Response to ¹⁷⁷ Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1336-1344.	3.6	95
34	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. <i>Neuroendocrinology</i> , 2017, 105, 281-294.	2.5	94
35	Salvage peptide receptor radionuclide therapy with [¹⁷⁷ Lu-DOTA,Tyr ³]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 704-717.	6.4	90
36	Paraneoplastic syndromes secondary to neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2010, 17, R173-R193.	3.1	89

#	ARTICLE	IF	CITATIONS
37	<i>MAFA</i> missense mutation causes familial insulinomatosis and diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1027-1032.	7.1	88
38	Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine, 2018, 59, 452-458.	5.0	88
39	Role of biomarker tests for diagnosis of neuroendocrine tumours. Nature Reviews Endocrinology, 2018, 14, 656-669.	9.6	84
40	Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. Journal of Molecular Endocrinology, 2015, 54, 137-147.	2.5	83
41	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Annals of Oncology, 2017, 28, 1309-1315.	1.2	82
42	Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3381-3389.	3.6	78
43	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. Neuroendocrinology, 2018, 107, 375-386.	2.5	78
44	Addisonian crisis and relative adrenal failure. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 143-147.	5.7	74
45	Low Accuracy of Tumor Markers for Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4143-4151.	3.6	74
46	Risk Factors for Meningitis After Transsphenoidal Surgery. Clinical Infectious Diseases, 1997, 25, 852-856.	5.8	69
47	Somatostatin receptor imaging for neuroendocrine tumors. Pituitary, 2006, 9, 243-248.	2.9	69
48	EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointestinal Endoscopy, 2015, 81, 159-167.e2.	1.0	69
49	Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. British Journal of Cancer, 2016, 114, 650-658.	6.4	69
50	Cerebrospinal Fluid Leakage During Transsphenoidal Surgery: Postoperative External Lumbar Drainage Reduces the Risk for Meningitis. Pituitary, 2004, 7, 89-93.	2.9	66
51	Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. European Journal of Endocrinology, 2016, 174, 271-280.	3.7	65
52	Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using ¹⁷⁷ Lu-DOTATATE. European Journal of Endocrinology, 2019, 181, 45-53.	3.7	63
53	Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1: Results From the Dutch MEN1 Study Group. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3795-3805.	3.6	60
54	Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronyltransferase isoenzymes. FEBS Letters, 1993, 324, 358-360.	2.8	59

#	ARTICLE	IF	CITATIONS
55	The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. <i>Clinical Endocrinology</i> , 2005, 63, 176-184.	2.4	59
56	Management of carcinoid syndrome: a systematic review and meta-analysis. <i>Endocrine-Related Cancer</i> , 2019, 26, R145-R156.	3.1	59
57	Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease. <i>Neurology</i> , 2012, 79, 793-796.	1.1	57
58	The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. <i>Neuroendocrinology</i> , 2018, 106, 357-365.	2.5	57
59	Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. <i>Endocrine-Related Cancer</i> , 2018, 25, L37-L42.	3.1	57
60	Carcinoid syndrome: diagnosis and medical management. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2005, 49, 850-860.	1.3	56
61	Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Clinical Features, Diagnosis, Management, and Follow-Up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3060-3069.	3.6	56
62	Adrenal Medullary Hyperplasia Is a Precursor Lesion for Pheochromocytoma in MEN2 Syndrome. <i>Neoplasia</i> , 2014, 16, 868-873.	5.3	55
63	New therapeutic options for metastatic malignant insulinomas. <i>Clinical Endocrinology</i> , 2011, 75, 277-284.	2.4	54
64	Peptide receptor radionuclide therapy of neuroendocrine tumours. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 103-114.	4.7	54
65	Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. <i>Drugs</i> , 2019, 79, 21-42.	10.9	54
66	Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm. <i>Annals of Surgery</i> , 2018, 267, 1155-1160.	4.2	51
67	Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. <i>Oncotarget</i> , 2018, 9, 14791-14802.	1.8	50
68	MEN1-Dependent Breast Cancer: Indication for Early Screening? Results From the Dutch MEN1 Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2083-2090.	3.6	49
69	ENDOCRINOLOGY IN PREGNANCY: Pheochromocytoma in pregnancy: case series and review of literature. <i>European Journal of Endocrinology</i> , 2017, 177, R49-R58.	3.7	48
70	Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 561-570.	10.7	48
71	Selenium Status Is Positively Associated with Bone Mineral Density in Healthy Aging European Men. <i>PLoS ONE</i> , 2016, 11, e0152748.	2.5	48
72	The History of Acromegaly. <i>Neuroendocrinology</i> , 2016, 103, 7-17.	2.5	45

#	ARTICLE	IF	CITATIONS
73	Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. <i>Endocrine-Related Cancer</i> , 2017, 24, 243-251.	3.1	45
74	Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886). <i>Pituitary</i> , 2009, 12, 236-244.	2.9	44
75	Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. <i>Endocrine-Related Cancer</i> , 2017, 24, R261-R274.	3.1	43
76	Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. <i>European Journal of Endocrinology</i> , 2005, 153, 67-71.	3.7	42
77	Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. <i>European Journal of Endocrinology</i> , 2016, 175, 361-366.	3.7	42
78	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995.	7.0	42
79	Effects of Somatostatin Analogs on a Growth Hormone-Releasing Hormone Secreting Bronchial Carcinoid, <i>in Vivo</i> and <i>in Vitro</i> Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 428-433.	3.6	41
80	Impact of Delay in Diagnosis in Outcomes in MEN1: Results From the Dutch MEN1 Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1159-1165.	3.6	41
81	Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. <i>Endocrine-Related Cancer</i> , 2018, 25, R115-R130.	3.1	41
82	Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2005, 19, 705-715.	2.4	39
83	Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. <i>Endocrine-Related Cancer</i> , 2014, 21, 653-661.	3.1	39
84	A short history of neuroendocrine tumours and their peptide hormones. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 3-17.	4.7	39
85	New developments in the medical treatment of Cushing's syndrome. <i>Endocrine-Related Cancer</i> , 2012, 19, R205-R223.	3.1	38
86	Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. <i>BMC Cancer</i> , 2019, 19, 325.	2.6	38
87	Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing's syndrome. <i>JCI Insight</i> , 2017, 2, .	5.0	38
88	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017, 105, 193-195.	2.5	37
89	Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas.. <i>Endocrine-Related Cancer</i> , 2004, 11, 19-34.	3.1	35
90	Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2018, 25, 245-254.	3.1	35

#	ARTICLE	IF	CITATIONS
91	Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. <i>Endocrine-Related Cancer</i> , 2019, 26, R157-R179.	3.1	34
92	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 813-824.	11.4	34
93	Neuroendocrine tumors and somatostatin: imaging techniques. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 132-6.	3.3	33
94	Adrenal Cushing's syndrome during pregnancy. <i>European Journal of Endocrinology</i> , 2017, 177, K13-K20.	3.7	32
95	Additional hepatic ¹⁷⁷ Lu-DOTATATE in patients with neuroendocrine tumours treated with ¹⁷⁷ Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). <i>BMC Gastroenterology</i> , 2018, 18, 84.	2.0	32
96	Heroes in endocrinology: Nobel Prizes. <i>Endocrine Connections</i> , 2014, 3, R94-R104.	1.9	31
97	Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors. <i>Endocrine</i> , 2003, 20, 285-290.	2.2	30
98	Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?. <i>Neuroendocrinology</i> , 2016, 103, 560-566.	2.5	30
99	Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. <i>Annals of Oncology</i> , 2016, 27, 746-747.	1.2	30
100	On the enterohepatic cycle of triiodothyronine in rats; importance of the intestinal microflora. <i>Life Sciences</i> , 1989, 45, 849-856.	4.3	29
101	High Fear of Disease Occurrence Is Associated With Low Quality of Life in Patients With Multiple Endocrine Neoplasia Type 1: Results From the Dutch MEN1 Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2354-2361.	3.6	29
102	Insulinoma. <i>Neuroendocrinology</i> , 2004, 80, 20-22.	2.5	28
103	Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments. <i>Neuroendocrinology</i> , 2017, 105, 394-402.	2.5	27
104	Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in Multiple Endocrine Neoplasia type 1: Results from the DutchMEN1 Study Group. <i>Pancreatology</i> , 2017, 17, 766-772.	1.1	26
105	DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment. <i>European Journal of Endocrinology</i> , 2018, 179, 153-160.	3.7	26
106	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. <i>Endocrine-Related Cancer</i> , 2014, 21, 601-613.	3.1	25
107	GEP-NETs update: Functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). <i>European Journal of Endocrinology</i> , 2014, 170, R173-R183.	3.7	24
108	Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2019, 26, 1-12.	3.1	24

#	ARTICLE	IF	CITATIONS
109	IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. <i>Endocrine</i> , 2019, 64, 673-684.	2.3	23
110	Peptide Receptor Radionuclide Therapy With ¹⁷⁷ Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3665-e3672.	3.6	23
111	Gut endocrine tumours. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004, 18, 477-495.	4.7	22
112	Carcinoid crisis during transesophageal echocardiography. <i>Intensive Care Medicine</i> , 2000, 26, 254-254.	8.2	21
113	Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. <i>Endocrine-Related Cancer</i> , 2016, 23, 727-737.	3.1	21
114	Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. <i>Clinical Endocrinology</i> , 2017, 87, 165-170.	2.4	21
115	Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for ¹²³ I-epidepride dopamine D2 receptor imaging?. <i>European Journal of Endocrinology</i> , 2006, 155, 717-723.	3.7	20
116	ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2009, 90, 159-161.	2.5	20
117	Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSC). <i>Journal of Surgical Oncology</i> , 2019, 120, 966-975.	1.7	20
118	Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 46-55.	3.6	19
119	Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the <i>MGMT</i> Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4574-4584.	3.6	18
120	MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 367-378.	3.1	16
121	Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, 585-599.	3.1	16
122	Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework. <i>Annals of Oncology</i> , 2017, 28, 3022-3027.	1.2	15
123	Health-Related Quality of Life in Patients with Multiple Endocrine Neoplasia Type 1. <i>Neuroendocrinology</i> , 2021, 111, 288-296.	2.5	15
124	Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2922-2929.	3.6	15
125	Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging. <i>Endocrine-Related Cancer</i> , 2020, 27, 615-624.	3.1	15
126	Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells. <i>Neuroendocrinology</i> , 2020, 110, 351-363.	2.5	14

#	ARTICLE	IF	CITATIONS
127	The Management of Neuroendocrine Tumors of the Lung in MEN1: Results From the Dutch MEN1 Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1014-e1027.	3.6	14
128	ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13044.	2.6	14
129	Critical appraisal of MGMT in digestive NET treated with alkylating agents. <i>Endocrine-Related Cancer</i> , 2020, 27, R391-R405.	3.1	14
130	5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. <i>Bone</i> , 2012, 50, 1260-1265.	2.9	13
131	The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 407-417.	3.6	13
132	Role of the tumor microenvironment in digestive neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, R519-R544.	3.1	13
133	Effects of thyroid status and thyrostatic drugs on hepatic glucuronidation of lodothyronines and other substrates in rats. <i>Endocrine</i> , 1996, 4, 79-85.	2.3	12
134	Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 1017-1024.	4.7	12
135	A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 807-816.	4.4	12
136	Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours. <i>Cancers</i> , 2021, 13, 443.	3.7	12
137	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. <i>European Journal of Cancer</i> , 2021, 144, 200-214.	2.8	12
138	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13040.	2.6	12
139	Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.5	12
140	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13105.	2.6	12
141	Somatostatin Receptors in Pheochromocytoma. , 2003, 31, 145-154.		11
142	Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells. <i>Neuroendocrinology</i> , 2016, 103, 815-825.	2.5	11
143	Expression of p27Kip1 and p18Ink4c in human multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 655-661.	3.3	11
144	Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1969-e1975.	3.6	11

#	ARTICLE	IF	CITATIONS
145	Thyroid incidentalomas in patients with multiple endocrine neoplasia type 1. <i>European Journal of Endocrinology</i> , 2015, 172, 337-342.	3.7	10
146	Effect of a single dose vitamin D3 on postprandial arterial stiffness and inflammation in vitamin D deficient women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2016-3394.	3.6	10
147	Potential value of EUS in pancreatic surveillance of VHL patients. <i>European Journal of Endocrinology</i> , 2016, 174, 611-620.	3.7	10
148	When and How to Use Somatostatin Analogues. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 549-555.	3.2	10
149	Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort Study. <i>Neuroendocrinology</i> , 2018, 107, 315-323.	2.5	10
150	Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells. <i>Hormones and Cancer</i> , 2019, 10, 107-119.	4.9	10
151	Inhibin Alpha-Subunit (INHA) Expression in Adrenocortical Cancer Is Linked to Genetic and Epigenetic INHA Promoter Variation. <i>PLoS ONE</i> , 2014, 9, e104944.	2.5	10
152	Operative Treatment of Primary Hyperparathyroidism in Daycare Surgery. <i>Scandinavian Journal of Surgery</i> , 2015, 104, 196-199.	2.6	8
153	Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells. <i>Endocrine</i> , 2016, 52, 664-667.	2.3	8
154	Oldest case of gigantism? Assessment of the alleged remains of Sa-Nakht, king of ancient Egypt. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 580-581.	11.4	8
155	Unmet Needs in the Field of Neuroendocrine Neoplasms of the Gastrointestinal Tract, Pancreas, and Respiratory System: Reports by the ENETS Group. <i>Neuroendocrinology</i> , 2019, 108, 5-6.	2.5	8
156	Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?. <i>Neuroendocrinology</i> , 2021, 111, 170-177.	2.5	8
157	Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. <i>Current Oncology Reports</i> , 2021, 23, 46.	4.0	8
158	Induction therapy with ¹⁷⁷ Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3203-3214.	6.4	8
159	Familial gigantism. <i>Clinics</i> , 2012, 67, 29-32.	1.5	7
160	Clues For Genetic Anticipation In Multiple Endocrine Neoplasia Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2491-e2500.	3.6	7
161	Pituitary hyperplasia: an uncommon presentation of a common disease. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2015, 2015, 150056.	0.5	7
162	ENETS standardized (synoptic) reporting in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13054.	2.6	7

#	ARTICLE	IF	CITATIONS
163	Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3313-e3320.	3.6	7
164	Multidisciplinary integrated care pathway for von Hippel-Lindau disease. <i>Cancer</i> , 2022, , .	4.1	7
165	Somatostatin Analogs as Radiodiagnostic Tools. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2005, 6, 23-27.	5.7	6
166	Acromegalic gigantism, physicians and body snatching. Past or present?. <i>Pituitary</i> , 2012, 15, 312-318.	2.9	6
167	No Association of Blood Type O With Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3850-3855.	3.6	6
168	Endocrinology and Art. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 392-392.	3.3	5
169	Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3515-3525.	3.6	5
170	Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?. <i>Endocrine Connections</i> , 2016, 5, 143-151.	1.9	4
171	Incidence and prognosis of carcinoid syndrome: hormones or tumour burden?. <i>Lancet Oncology</i> , The, 2017, 18, e299.	10.7	4
172	From dwarves to giants: South American's contribution to the history of growth hormone and related disorders. <i>Growth Hormone and IGF Research</i> , 2020, 50, 48-56.	1.1	4
173	Importance of Complete Pathology Reporting for Neuroendocrine Carcinoma: WHO Guidelines Are a Good Start but Not Enough. <i>Neuroendocrinology</i> , 2020, 110, 994-1000.	2.5	4
174	The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study. <i>Endocrine</i> , 2020, 68, 640-649.	2.3	4
175	Predicting symptomatic mesenteric mass in small intestinal neuroendocrine tumors using radiomics. <i>Endocrine-Related Cancer</i> , 2021, 28, 529-539.	3.1	4
176	Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. <i>Annals of Surgical Oncology</i> , 2022, 29, 5568-5577.	1.5	4
177	Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study. <i>European Journal of Endocrinology</i> , 2022, , .	3.7	4
178	Leucocyte-bound apolipoprotein B in the circulation is inversely associated with the presence of clinical and subclinical atherosclerosis. <i>European Journal of Clinical Investigation</i> , 2016, 46, 690-697.	3.4	3
179	Erythrocyte-bound apolipoprotein B in atherosclerosis and mortality. <i>European Journal of Clinical Investigation</i> , 2017, 47, 289-296.	3.4	3
180	Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2021, 2021, , .	0.5	3

#	ARTICLE	IF	CITATIONS
181	Epidemiological, clinical and endoscopic characteristics of colorectal neuroendocrine neoplasms: a population-based study in the Netherlands. <i>Endoscopy International Open</i> , 2022, 10, E940-E951.	1.8	3
182	Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases. <i>Endocrine-Related Cancer</i> , 2022, 29, 241-250.	3.1	3
183	Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres. <i>European Journal of Cancer Care</i> , 2022, 31, .	1.5	3
184	Energy and metabolic alterations in predisposition to pheochromocytomas and paragangliomas: the so-called Warburg (and more) effect, 15 years on. <i>Endocrine-Related Cancer</i> , 2015, 22, E5-E7.	3.1	2
185	Saint Wilgefortis: sudden hirsutism to prevent an unwanted marriage. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 1475-1475.	3.3	2
186	Pareidolia in Neuroendocrinology: A Pituitary Macroadenoma Resembling "Big Bird". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1348-1349.	3.6	2
187	Turning Up the Heat: Endoscopic Ablation of Pancreatic Neuroendocrine Neoplasms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5053-5055.	3.6	2
188	Hereditary acromegalic gigantism in the family of Roman Emperor Maximinus Thrax. <i>Medical Hypotheses</i> , 2020, 136, 109525.	1.5	2
189	Should everolimus be stopped after radiological progression in metastatic insulinoma? A "pro" point of view. <i>Endocrine</i> , 2021, 71, 256-257.	2.3	2
190	The acromegalic? Giant Samuel MacDonald and the short stature George Cranstoun by John Kay. <i>Journal of Endocrinological Investigation</i> , 2021, , 1.	3.3	2
191	Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Cancer, Supplement</i> , 2021, 16, 5-13.	2.2	2
192	The Surprising Irish Giant of St. James's Street by Thomas Rowlandson. The acromegalic giant Patrick Cotter (1760-1806). <i>Journal of Endocrinological Investigation</i> , 2022, , 1.	3.3	2
193	Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus. <i>European Journal of Endocrinology</i> , 2022, 186, 597-605.	3.7	2
194	4 Movie Actors with Acromegaly/Gigantism. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 791-792.	3.3	1
195	Letter to the Editor: "The Inflammation-Based Index Can Predict Response and Improve Patient Selection in NETs Treated With PRRT: A Pilot Study". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5104-5105.	3.6	1
196	Outcomes after Tricuspid Valve Replacement for Carcinoid Heart Disease: A Multicenter Study. <i>Structural Heart</i> , 2020, 4, 122-130.	0.6	1
197	Aldo Molinari: the wedding of the giant Almiro Crema in Torino. <i>Journal of Endocrinological Investigation</i> , 2021, , 1.	3.3	1
198	Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patients. <i>European Journal of Endocrinology</i> , 2022, , .	3.7	1

#	ARTICLE	IF	CITATIONS
199	Neuroendocrine Tumors. , 0, , 564-668.		0
200	P51. Pregnancy stimulates cerebellar hemangioblastoma growth in von Hippel-Lindau disease. Pregnancy Hypertension, 2011, 1, 297.	1.4	0
201	The need for national registries for rare endocrine tumor syndromes. Endocrine, 2017, 58, 205-206.	2.3	0
202	Melena in a Patient With a Metastasized Neuroendocrine Tumor. Gastroenterology, 2018, 154, e6-e7.	1.3	0
203	Insulinoma. , 2019, , 58-62.		0
204	Response to Prof. Ingo Brink and Prof. Aubalewska-Dydejczyk regarding Their "Letter to the Editor" Neuroendocrinology, 2019, 108, 366-366.	2.5	0
205	Clémentine Delait (1865-1934), the most famous bearded lady on the continent in the 20th century. Gynecological Endocrinology, 2020, 36, 213-217.	1.7	0
206	Toni Mochty: Bardet Biedl syndrome "avant la lettre" Clinical Genetics, 2020, 97, 536-537.	2.0	0
207	Neuroendocrine Neoplasms (NENs) in Complex Genetic Disorders. Endocrinology, 2021, , 361-373.	0.1	0
208	INTENSIVE: InterNational Registry of SARS-CoV-2 positive neuroendocrine neoplasm patients.. Journal of Clinical Oncology, 2021, 39, e16205-e16205.	1.6	0
209	Medical treatment of neuroendocrine neoplasms. Current Opinion in Endocrine and Metabolic Research, 2021, 18, 139-144.	1.4	0
210	A circus postcard showing short statue in a clown and a horse. Journal of Endocrinological Investigation, 2021, , 1.	3.3	0
211	Neuroendocrine Neoplasms (NENs) in Complex Genetic Disorders. Endocrinology, 2019, , 1-13.	0.1	0
212	Editorial: Early Genetic and Clinical Diagnosis in MEN1. Frontiers in Endocrinology, 2020, 11, 218.	3.5	0
213	The possibilities and impossibilities of treating acromegaly 50 years ago illustrated by Diane Arbus, A Jewish Giant at Home with his Parents, 1970. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	0